Biotechnology companies stocks report

Biotechnology companies stocks report

March 13, 2017 Off By Dino Mustafić

Pre-market, navigates the Biotechnology space with focus on Nektar Therapeutics, Seattle Genetics Inc., Dynavax Technologies Corp. , and BioMarin Pharmaceutical Inc..

According to a Barron’s report, the iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.

Nektar Therapeutics revenue halved in 2016

California-headquartered Nektar Therapeutics’ stock climbed 0.13%, finishing last Friday’s trading session at $15.34. A total volume of 1.09 million shares was traded. The company’s shares have surged 16.74% in the last month, 24.41% over the previous three months, and 25.02% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 17.08% and 3.43%, respectively. Additionally, shares of Nektar Therapeutics, which develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the US, have a Relative Strength Index (RSI) of 65.66.

On March 01st, 2017, Nektar Therapeutics announced revenue of $37.5 million for Q4 2016 compared to $39.4 million in Q4 2015. The company’s revenue for the year ended December 31, 2016, was $165.4 million compared to $230.8 million in full year 2015. Nektar Therapeutics’ net loss for Q4 2016 was $42.2 million, or $0.28 loss per share, compared to a net loss of $54.1 million, or $0.40 loss per share, in Q4 2015.

Seattle Genetics’ shares advanced 10.49% in the past month

Shares in Washington headquartered Seattle Genetics Inc. ended at $67.96, rising 1.28% from the last trading session. The stock recorded a trading volume of 621,241 shares. The company’s shares have advanced 10.49% in the past month, 4.41% in the previous three months, and 28.79% on an YTD basis. The stock is trading 11.83% and 26.66% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Seattle Genetics, which develops and commercializes targeted therapies to treat cancer worldwide, have an RSI of 61.23.

On March 06th, 2017, Seattle Genetics announced that the US Food and Drug Administration (FDA) has lifted the clinical hold announced on December 27, 2016, on phase-1 trials of vadastuximab talirine (SGN-CD33A; 33A) in acute myeloid leukemia (AML). Seattle Genetics will resume two phase-1 trials of vadastuximab talirine. The first is combination treatment with standard of care, or 7+3, chemotherapy in newly diagnosed younger AML patients and the second is monotherapy and combination treatment with hypomethylating agents in both newly diagnosed and relapsed AML patients.

Dynavax Technologies’ shares gained 47.50% in the last two months

On Friday, shares in California headquartered Dynavax Technologies Corp. recorded a trading volume of 689,560 shares. The stock closed the day flat at $5.90. The company’s shares have gained 47.50% in the last one month, 18.00% over the previous three months, and 49.37% on an YTD basis. The stock is trading 34.29% above its 50-day moving average. Additionally, shares of Dynavax Technologies, which discovers and develops novel vaccines and therapeutics in the US, have an RSI of 66.77.

On February 28th, 2017, Dynavax announced that the US FDA has accepted for review Dynavax’s responses to the Complete Response Letter issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company’s vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older.

BioMarin Pharma revenues 32% up year over year

At the close of trading on Friday, shares in California-headquartered BioMarin Pharmaceutical Inc. recorded a trading volume of 870,538 shares. The stock finished the session 1.73% higher at $92.53. The company’s shares have gained 1.79% in the past month, 14.21% in the previous three months, and 11.70% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.74% and 4.03%, respectively. Furthermore, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 54.84.

On February 23rd, 2017, BioMarin Pharmaceutical announced that for Q4 2016, GAAP net loss was $91 million, or ($0.53) per basic and diluted share, compared to GAAP net income of $69 million, or $0.43 and $0.39 per basic and diluted share, respectively, for Q4 2015. For Q4 2016, total BioMarin Pharma’s revenues were $300 million, up 32% on a y-o-y basis.

On March 02nd, 2017, research firm Instinet initiated a ‘Neutral’ rating on the Company’s stock, with a target price of $93 per share.